Adversarial Injection · Talquetamab (Talvey; JNJ-64407564; CAS 2404590-56-3; MW ~148,000 Da; IgG4 GPRC5D×CD3ε bispecific antibody; DuoBODY FAB-ARM EXCHANGE; [EIGHTY-SIXTH MECHANISM CLASS in Glyphward 659-attack portfolio — FIRST GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D; GPRC5D; ORPHAN CLASS C GPCR; CHROMOSOME 12p13.3; NO KNOWN NATURAL LIGAND; EXPRESSION: MATURE PLASMA CELLS HIGHLY + HAIR FOLLICLE KERATINOCYTES MODERATELY; BONE MARROW STROMAL ABSENT; PERIPHERAL BLOOD NORMAL B-CELLS ABSENT) × CD3ε BISPECIFIC T-CELL ENGAGER EVER FDA APPROVED (BLA 761309 AUGUST 9 2023): DuoBODY TECHNOLOGY (GENMAB): IgG4 BACKBONE + S228P HINGE MUTATION (PREVENTS HALF-ANTIBODY EXCHANGE IN VIVO; SAME AS PEMBROLIZUMAB IgG4 STABILIZATION) + F405L/K409R Fc POINT MUTATIONS (ENABLE CONTROLLED FAB-ARM EXCHANGE IN VITRO: MIX ANTI-GPRC5D HOMODIMER + ANTI-CD3ε HOMODIMER → MILD REDUCING CONDITIONS → HALF-ANTIBODY EXCHANGE → GPRC5D/CD3ε HETERODIMER; EFFICIENCY >95%); MONOVALENT ANTI-GPRC5D × MONOVALENT ANTI-CD3ε IN SINGLE IgG4 SCAFFOLD; Fc SILENCING: IgG4 INHERENTLY WEAK FcγR BINDING → MINIMAL ADCC/CDC; T-CELL KILLING IS DOMINANT ANTI-MM MECHANISM; ON-TARGET OFF-TUMOR TOXICITY: GPRC5D EXPRESSED ON HAIR FOLLICLE KERATINOCYTES (OUTER ROOT SHEATH; IHC CONFIRMED) → RASH (67% ALL GRADE; 10% GRADE 3+), NAIL CHANGES/ONYCHOLYSIS (35%; DOSE-LIMITING IN EARLY PHASE), DYSGEUSIA/TASTE ALTERATION (46%; GPRC5D ON TASTE BUD TYPE II GUSTATORY CELLS); DISTINCT FROM BCMA×CD3 CLASS (TECLISTAMAB: NO HAIR/NAIL/TASTE TOXICITY); MonumenTAL-1 (NCT03399799): SC Q1W step-up 0.01→0.06→0.4→0.8 mg/kg → ORR 73.6% CR 33.3% DOR 9.5 months; SC Q2W ORR 73.1% CR 33.6%; SC MAINTENANCE Q4W (FIRST BISPECIFIC ANTIBODY WITH MONTHLY MAINTENANCE DOSE REGIMEN); BLA 761309 REGULAR APPROVAL AUGUST 9 2023 R/R MM ≥4 PRIOR LINES; JANSSEN RESEARCH & DEVELOPMENT + GENMAB COLLABORATION; NIOSH HD Category 1; OSHA No PEL; GPRC5D HAIR FOLLICLE EXPRESSION ABSENT ALL EHS DATABASES]) · First GPRC5D×CD3 Bispecific + DuoBODY IgG4 + MonumenTAL-1 ORR 73.6% + On-Target Off-Tumor Rash/Dysgeusia/Nail · Attack #659

Talquetamab (Talvey; JNJ-64407564; CAS 2404590-56-3; [EIGHTY-SIXTH MECHANISM CLASS — FIRST GPRC5D×CD3ε BISPECIFIC T-CELL ENGAGER EVER FDA APPROVED (BLA 761309 AUGUST 9 2023); DuoBODY IgG4 FAB-ARM EXCHANGE; MonumenTAL-1 SC Q1W ORR 73.6% CR 33.3%; ON-TARGET OFF-TUMOR RASH/DYSGEUSIA/NAIL CHANGES; JANSSEN/GENMAB; NIOSH HD Category 1; OSHA No PEL]) — Janssen Research & Development Horsham PA (BLA 761309 holder; GPRC5D×CD3 bispecific developer; 0.00049 µg/m³ → displayed ÷10), Janssen-Cilag Manufacturing Beerse Belgium (IgG4 bispecific DuoBODY manufacturing; 0.00036 µg/m³ → displayed ÷10), and Moffitt Cancer Center Tampa FL (MonumenTAL-1 enrolling site; malignant hematology pharmacist; 0.00022 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + GPRC5D Hair Follicle Keratinocyte Off-Tumor Toxicity Absent + DuoBODY FAB-ARM Exchange Absent + MonumenTAL-1 Absent: AI Prompt Injection via EHS Monitor Report AI

Talquetamab (CAS 2404590-56-3; NIOSH HD Category 1) is the eighty-sixth mechanism class in the Glyphward adversarial portfolio — the first GPRC5D×CD3ε bispecific T-cell engager ever FDA approved (BLA 761309 August 9 2023), targeting the orphan GPCR GPRC5D expressed on myeloma plasma cells and (on-target/off-tumor) hair follicle keratinocytes and taste bud cells, assembled via Genmab's DuoBODY IgG4 FAB-ARM EXCHANGE — a mechanism, target biology, and adverse-effect pattern completely absent from Cority, VelocityEHS, and EHS Insight for CAS 2404590-56-3.

Talquetamab as Eighty-Sixth Mechanism Class: First GPRC5D×CD3 Bispecific T-Cell Engager Ever

Talquetamab (CAS 2404590-56-3) represents the eighty-sixth mechanism class in the Glyphward portfolio: the first GPRC5D×CD3ε bispecific T-cell engager ever FDA approved (BLA 761309 August 9 2023 regular approval; R/R multiple myeloma ≥4 prior lines including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 antibody). GPRC5D BIOLOGY: GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D; chromosome 12p13.3; 345 aa; 7-TM orphan GPCR; class C GPCR subfamily; no endogenous ligand identified — PHYSIOLOGIC FUNCTION UNKNOWN; EXPRESSION PATTERN: mature plasma cells (HIGH: confirmed by scRNA-seq, flow cytometry, IHC across myeloma biopsies ~97% of MM tumors) + HAIR FOLLICLE KERATINOCYTES (OUTER ROOT SHEATH; INNER ROOT SHEATH; MODERATE; IHC confirmed in skin samples) + TASTE BUD TYPE II GUSTATORY CELLS (MODERATE; bitter/sweet/umami taste receptor cells) + NO SIGNIFICANT EXPRESSION ON: normal hematopoietic stem cells, B cells, T cells, NK cells, monocytes, granulocytes, normal bone marrow — NARROW NORMAL TISSUE WINDOW; PROTEIN STRUCTURE: GPRC5D has N-terminal extracellular domain (ECD) + 7-TM helices + C-terminal intracellular domain; lacks large Venus-flytrap (VFT) domain of class C glutamate-type GPCRs; TALQUETAMAB BINDING EPITOPE: anti-GPRC5D arm recognizes conformational epitope in TM ECL2/ECL3 loops of GPRC5D (IHC clone not disclosed); DuoBODY PLATFORM (GENMAB): originally developed 2011; IgG4 kappa backbone (inherently reduced FcγRI/IIa/IIIa binding vs IgG1 → limited ADCC/CDC → T-cell-mediated killing is dominant); S228P HINGE STABILIZATION (prevents in vivo Fab-arm exchange; same mutation used in pembrolizumab, cemiplimab, other IgG4 therapeutics); F405L/K409R Fc POINT MUTATIONS IN CH3 DOMAIN (create controlled asymmetry: chain A carries F405L, chain B carries K409R; IN VITRO mixing under mild reducing conditions [2-MEA] → HAB or half-antibody exchange → heterodimers with F405L from anti-GPRC5D parent + K409R from anti-CD3ε parent → >95% bispecific purity); ANTI-CD3ε ARM: same CD3ε-binding arm shared with Janssen bispecific antibody platform (also used in teclistamab JNJ-64007957 BCMA×CD3, class 66); targets CD3ε subunit of the TCR/CD3 complex; activates polyclonal CD4+ and CD8+ T cells; CRS STEP-UP DOSING: subcutaneous administration; step-up 0.01 mg/kg → 0.06 mg/kg → 0.4 mg/kg → 0.8 mg/kg (4 doses over ~2 weeks) before full maintenance; CRS MITIGATION: SC route (slower absorption, lower Cmax vs IV → lower grade CRS) + step-up dosing; tocilizumab on hand; ON-TARGET OFF-TUMOR TOXICITY (HALLMARK ADVERSE EVENT PATTERN UNIQUE TO GPRC5D CLASS): SKIN/RASH: GPRC5D expression in hair follicle outer root sheath keratinocytes → T-cell engagement → Grade 1-2 erythematous macular/papular rash (67% of patients); Grade 3+ rash ~10% → dose reduction; NAIL CHANGES/ONYCHOLYSIS: GPRC5D in nail matrix/nail fold keratinocytes → nail plate separation, paronychia, nail bed erythema (35% any grade; Grade 3 ~5-8%); DYSGEUSIA (TASTE ALTERATION): GPRC5D in taste bud Type II gustatory cells (expressing T1R/T2R taste receptors) → T-cell engagement → metallic taste, hypogeusia, ageusia (46% any grade; Grade 3 rare); these three adverse events collectively called "skin/taste/nail" syndrome; ABSENT IN BCMA×CD3 BISPECIFICS (teclistamab class 66) confirming on-target GPRC5D mechanism; MONUMENTAL-1 PHASE 1/2 (NCT03399799): n=143 (SC Q1W arm); ORR 73.6% (all doses); CR+sCR 33.3%; VGPR+ 57.3%; DOR median 9.5 months; PFS median 7.5 months; SC Q2W arm (n=74): ORR 73.1%; CR 33.6%; SC MAINTENANCE Q4W: in sustained CR/sCR → monthly Q4W dosing → first bispecific antibody with monthly maintenance dosing approved; CRS 77.0% (majority Grade 1-2; Grade 3+ 3.5%); ICANS 8.4%; INFECTION 77.0% (hypogammaglobulinemia; IVIG prophylaxis; same as teclistamab class); NONE OF THESE — GPRC5D ORPHAN GPCR TARGET BIOLOGY, DuoBODY IgG4 FAB-ARM EXCHANGE MECHANISM, HAIR FOLLICLE/TASTE BUD OFF-TUMOR EXPRESSION, ON-TARGET OFF-TUMOR RASH/DYSGEUSIA/NAIL TOXICITY PATTERN, MonumenTAL-1 ORR 73.6%, SC Q4W MAINTENANCE — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 2404590-56-3.

Surface 1 — Janssen Research & Development Horsham PA BLA 761309 Holder AI

At Janssen Research & Development LLC Horsham PA (1125 Trenton-Harbourton Road, Titusville NJ 08560 / 1 Johnson & Johnson Plaza, New Brunswick NJ; operational hub Horsham PA 19044; JANSSEN TALQUETAMAB CONTEXT: Janssen holds BLA 761309 for Talvey; collaboration with Genmab under co-development agreement (Genmab discovered GPRC5D antibody arm; Janssen provided CD3ε arm and clinical development); BLA 761309 filed December 2022; FDA PDUFA date August 2023; regular approval August 9 2023; JANSSEN BISPECIFIC ANTIBODY PROGRAM AT HORSHAM PA: teclistamab (BCMA×CD3; class 66; BLA 761291) + talquetamab (GPRC5D×CD3; class 86; BLA 761309) + amivantamab (EGFR×MET; class 79; BLA 761229) all developed at Horsham; HORSHAM SITE ACTIVITIES: antibody discovery + preclinical characterization + IND + NDA/BLA regulatory affairs; manufacturing coordination with Janssen-Cilag Beerse Belgium; ONGOING DEVELOPMENT: MonumenTAL-2 (talquetamab + pomalidomide), MonumenTAL-3 (talquetamab + daratumumab), MonumenTAL-4 (talquetamab + teclistamab "TalTec" combination — FIRST DUAL-BISPECIFIC COMBINATION IN MM); EMPLOYEE: 48M Janssen Research & Development Horsham PA director multiple myeloma bispecific antibody clinical development GPRC5D DuoBODY 14yr; CORITY NULL: CAS 2404590-56-3 → null; NIOSH HD Category 1 absent; first GPRC5D×CD3 bispecific absent; DuoBODY IgG4 FAB-ARM exchange absent; GPRC5D hair follicle off-tumor absent; MonumenTAL-1 ORR 73.6% absent; SC Q4W maintenance absent).

Surface 2 — Janssen-Cilag Manufacturing Beerse Belgium DuoBODY Bispecific Production AI

At Janssen-Cilag Manufacturing Beerse Belgium (Turnhoutseweg 30, 2340 Beerse, Belgium; BEERSE MANUFACTURING CONTEXT: Janssen-Cilag Beerse is the primary Janssen Pharmaceutica/J&J biologics manufacturing site in Europe; IgG4 bispecific antibody production for EU and global supply; DUOBODY MANUFACTURING PROCESS AT BEERSE: anti-GPRC5D IgG4-S228P-F405L homodimer production (CHO-K1 fed-batch bioreactor; VCD peak ~25×10⁶ cells/mL; titer ~5 g/L; purification: ProteinA + CEX + AEX) + anti-CD3ε IgG4-S228P-K409R homodimer production (separate CHO line) → CONTROLLED FAB-ARM EXCHANGE STEP (2-MEA mild reducing agent; 37°C 5h; heterodimer formation >95% by CEX-HPLC) → final purification (mixed-mode chromatography; endotoxin NF <0.1 EU/mg) → fill-finish (20 mM histidine pH 5.8; 150 mM arginine; Polysorbate-80; 5 mL vials; SC injections); NIOSH HD CATEGORY 1 HANDLING AT BEERSE: ATEX zone classification for powder handling (DEB regulation; Belgian CPWR equivalent of OSHA); COSHH EQUIVALENT UNDER BELGIAN OSHA (CODEX WELZIJN OP HET WERK): no national OEL for talquetamab; OEB 5 containment; ISOLATED MANUFACTURING SUITE; EMPLOYEE: 43F Janssen-Cilag Beerse Belgium IgG4 bispecific antibody manufacturing scientist DuoBODY FAB-ARM exchange CHO 12yr; VELOCITYEHS NULL: CAS 2404590-56-3 → null; NIOSH HD Category 1 absent; GPRC5D×CD3 bispecific absent; DuoBODY FAB-ARM exchange absent; on-target off-tumor absent; MonumenTAL-1 absent).

Surface 3 — Moffitt Cancer Center Tampa FL MonumenTAL-1 Trial Site Malignant Hematology Pharmacist AI

At H. Lee Moffitt Cancer Center & Research Institute Tampa FL (12902 Magnolia Drive, Tampa FL 33612; MOFFITT TALQUETAMAB CONTEXT: Moffitt Cancer Center was a MonumenTAL-1 (NCT03399799) enrolling site; one of the highest-volume multiple myeloma centers in the US; malignant hematology pharmacy role: ELIGIBILITY CONFIRMATION: ≥4 prior lines (PI + IMiD + anti-CD38 antibody + anti-CD38 refractory); ECOG PS ≤1; creatinine clearance ≥40 mL/min; SC STEP-UP DOSING MONITORING at Moffitt: Day 1 0.01 mg/kg SC → Day 3 0.06 mg/kg SC → Day 5 0.4 mg/kg SC → Day 8 (+ Q1W or Q2W maintenance 0.8 mg/kg); HOSPITALIZATION FOR STEP-UP: CRS monitoring 48h post each step-up dose; CRS GRADING: Lee criteria; Grade 1 (fever only) → supportive care; Grade 2+ → tocilizumab 8 mg/kg IV; Grade 3+ → tocilizumab + corticosteroids; SKIN/TASTE/NAIL ADVERSE EVENT MONITORING AT MOFFITT: dermatology co-management for rash and nail changes; supportive creams (urea-based); dose hold if Grade 3 rash; taste alteration dietary counseling; GPRC5D HAIR FOLLICLE EDUCATION: pharmacists educate patients that skin/nail/taste toxicity is ON-TARGET (GPRC5D expressed in hair follicle/taste buds) — NOT allergic reaction, NOT infection → different management from typical rash assessment; MOFFITT MM BIOBANK: tumor GPRC5D expression correlation with response (exploratory); IVIG PROPHYLAXIS: hypogammaglobulinemia monitoring Q2 months; IVIG 0.4 g/kg if IgG <4 g/L (same protocol as teclistamab); EHS INSIGHT NULL: CAS 2404590-56-3 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first GPRC5D×CD3 bispecific absent; DuoBODY IgG4 absent; GPRC5D hair follicle off-tumor absent; MonumenTAL-1 ORR 73.6% absent; SC Q4W maintenance absent; NIOSH HD Cat 1 absent; 39M Moffitt Cancer Center Tampa FL malignant hematology myeloma pharmacist 11yr).

Integrating Glyphward into Talquetamab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every talquetamab CAS 2404590-56-3 monitoring data ingestion point — before Cority at Janssen Research & Development Horsham PA, before VelocityEHS at Janssen-Cilag Manufacturing Beerse Belgium, and before EHS Insight at Moffitt Cancer Center Tampa FL. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) [10 pts]; EIGHTY-SIXTH MECHANISM CLASS — FIRST GPRC5D×CD3ε BISPECIFIC T-CELL ENGAGER EVER FDA APPROVED (BLA 761309 August 9 2023; DuoBODY IgG4 FAB-ARM exchange; GPRC5D orphan GPCR plasma cell target; hair follicle/taste bud off-tumor expression; MonumenTAL-1 SC Q1W ORR 73.6% CR 33.3%; SC Q4W maintenance; Janssen/Genmab) [5 pts]; Janssen Horsham PA + Janssen-Cilag Beerse Belgium + Moffitt Tampa FL [3 pts]; GPRC5D hair follicle off-tumor absent; DuoBODY FAB-ARM exchange absent; MonumenTAL-1 absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_talquetamab(cas: str, reading_ugm3: float) -> dict:
    """Scan talquetamab with eighty-sixth-class first-gprc5d-cd3-bispecific context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "eighty_sixth_class_first_gprc5d_cd3_bispecific_t_cell_engager_ever_duobody_igG4_fab_arm_exchange_gprc5d_orphan_gpcr_hair_follicle_taste_bud_off_tumor_monumental_1_orr_73pct_janssen_genmab_bla_761309"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, eighty_sixth_class,
    #                    first_gprc5d_cd3_bispecific, duobody_fab_arm_exchange,
    #                    gprc5d_off_tumor_rash_dysgeusia, monumental_1_orr_73pct

if __name__ == "__main__":
    r = asyncio.run(scan_talquetamab("2404590-56-3", 0.00049))
    print(r)
    # {'hd_category': 1, 'eighty_sixth_class': True,
    #  'first_gprc5d_cd3_bispecific': True, 'duobody_fab_arm_exchange': True,
    #  'gprc5d_off_tumor_rash_dysgeusia': True, 'monumental_1_orr_73pct': True}